Measurement of Antibodies to Interferon Beta in Patients With Multiple Sclerosis
Andrew R. Pachner, MD
From the Department of Neurosciences, University of Medicine and Dentistry of New Jersey Medical School, Newark.
Arch Neurol. 2001;58:1299-1300.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
THE NEUROLOGIST, like an Argonaut in his search for the Golden Fleece, has through the years been doggedly trying to achieve his lofty goal of optimally treating his or her patients with multiple sclerosis (MS). Progress has been made. A recombinant cytokine, interferon beta (administered as Betaseron or Avonex), has been widely used in the past decade and is the first recombinant protein extensively prescribed by neurologists. It is thus a "pioneer" therapy from which we all need to learn as much as possible before the next recombinant protein is available.
The injected protein is not identical to the human protein, and most treated patients make antibodies (ABs) that bind to interferon beta. Some of these binding ABs (BABs) are also neutralizing ABs (NABs) that block the effect of interferon beta in vitro. Because there is a high likelihood that ABs affect how well patients respond . . . [Full Text of this Article]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Multiple sclerosis: Relating MxA transcription to anti-interferon-{beta}-neutralizing antibodies
Hoffmann et al.
Neurology 2007;68:958-959.
FULL TEXT
An improved ELISA for screening for neutralizing anti-IFN-{beta} antibodies in MS patients
Pachner
Neurology 2003;61:1444-1446.
ABSTRACT
| FULL TEXT
Anti-IFN BAb and NAb antibodies: A minireview
Bendtzen
Neurology 2003;61:S6-10.
FULL TEXT
|
